{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:42:02Z","timestamp":1792730522704,"version":"4.5.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antidiabetic drugs lower blood glucose levels and may also have neuroprotective and vascular protection effects. In particular, sodium\u2013glucose cotransporter 2 inhibitors (SGLT2is) and incretin mimetics have demonstrated dementia-reducing effects. We evaluated whether SGLT2is reduce dementia risk compared with incretin mimetics in patients with type 2 diabetes (T2D).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis were performed by searching the PubMed, Embase, and Cochrane Library databases through February 2025. Both randomized trials and cohort studies were identified and qualitatively assessed, but only cohort studies were included in the quantitative meta-analysis. We also compared the effects of SGLT2is with those of dipeptidyl peptidase-4 inhibitors (DPP-4i) or glucagon-like peptide-1 receptor agonists (GLP-1RA) on dementia incidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nine studies were identified for analysis. Compared with incretin mimetics, SGLT2is significantly reduced the overall dementia risk [hazard ratio (HR) 0.82, 95% CI: 0.73-0.91], and SGLT2is had stronger effects than DPP-4i (HR 0.67, 95% CI: 0.59-0.77) and GLP-1RA (HR 0.93, 95% CI: 0.86-1.00). SGLT2i also reduced the risks of vascular dementia and Alzheimer\u2019s disease (HR 0.49, 95% CI: 0.35\u20130.70 vs. HR 0.68, 95% CI: 0.52\u20130.88, respectively). The results of subgroup analyses revealed increased benefits for patients aged older than 65 years. Empagliflozin was the most consistently protective among the SGLT2i agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SGLT2is may provide neuroprotective benefits beyond glycemic control in patients with T2D, particularly in older populations at higher risk of cognitive decline. These findings support consideration of SGLT2is as a preferred therapeutic option for patients with T2D at increased risk of dementia, although randomized controlled trials would further strengthen this evidence base.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42024567890<\/jats:uri>\n                      identifier PROSPERO (CRD420251037959).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1695075","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:29:18Z","timestamp":1761715758000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparative effects of SGLT2 inhibitors and incretin-based therapies on dementia risk in type 2 diabetes: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Kirim","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayeon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyun","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Mi","family":"Ah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Hee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e76498","DOI":"10.7759\/cureus.76498","article-title":"The pathophysiology and vascular complications of diabetes in chronic kidney disease: A comprehensive review","volume":"16","author":"Hauwanga","year":"2024","journal-title":"Cureus"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30267-9","article-title":"The link between type 2 diabetes and dementia: from biomarkers to treatment","volume":"8","author":"Beeri","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B4","first-page":"213","article-title":"Type 2 diabetes mellitus and cognitive impairment","volume":"53","author":"Damanik","year":"2021","journal-title":"Acta Med Indonesiana"},{"key":"B5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13098-024-01346-4","article-title":"The relationship between diabetes and the dementia risk: a meta-analysis","volume":"16","author":"Cao","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"B6","doi-asserted-by":"publisher","first-page":"112158","DOI":"10.1016\/j.diabres.2025.112158","article-title":"IDF global clinical practice recommendations for managing type 2 diabetes - 2025","author":"Schwarz","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"B7","doi-asserted-by":"publisher","first-page":"04156","DOI":"10.7189\/jogh.15.04156","article-title":"Global incidence trends and projections of Alzheimer disease and other dementias: an age-period-cohort analysis 2021","volume":"15","author":"Xu","year":"2025","journal-title":"J Glob Health"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.3390\/ijms23073651","article-title":"An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors","volume":"23","author":"Salvatore","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint16060124","article-title":"New insights into the role of SGLT-2 inhibitors in the prevention of dementia","volume":"16","author":"Hung","year":"2024","journal-title":"Neurol Int"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.3390\/biomedicines12081750","article-title":"Impact of sodium glucose cotransporter 2 inhibitors (SGLT2i) therapy on dementia and cognitive decline","volume":"12","author":"Lardaro","year":"2024","journal-title":"Biomedicines"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15918","article-title":"Association of sodium-glucose cotransporter 2 inhibitors with risk of incident dementia and all-cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks","volume":"26","author":"Pai","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14015","article-title":"Cognitive protection of incretin-based therapies in patients with type\u20092 diabetes mellitus: A systematic review and meta-analysis based on clinical studies","volume":"14","author":"Chai","year":"2023","journal-title":"J Diabetes Investig"},{"key":"B13","doi-asserted-by":"publisher","first-page":"9294113","DOI":"10.1155\/2024\/9294113","article-title":"Effects of DPP4 inhibitors as neuroprotective drug on cognitive impairment in patients with type 2 diabetes mellitus: A meta-analysis and systematic review","volume":"2024","author":"Yuan","year":"2024","journal-title":"Int J Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14313","article-title":"Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US","volume":"20","author":"Wang","year":"2024","journal-title":"Alzheimers Dement"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2024-004541","article-title":"Association between use of sodium-glucose co-transporter-2 inhibitor and the risk of incident dementia: a population-based cohort study","volume":"13","author":"Abdullah","year":"2025","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B16","doi-asserted-by":"publisher","first-page":"102726","DOI":"10.1016\/j.eclinm.2024.102726","article-title":"12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study","volume":"74","author":"De Giorgi","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7326\/M23-3220","article-title":"Sodium-glucose cotransporter-2 inhibitors, dulaglutide, and risk for dementia: A population-based cohort study","volume":"177","author":"Hong","year":"2024","journal-title":"Ann Intern Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"101581","DOI":"10.1016\/j.diabet.2024.101581","article-title":"Sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase IV inhibitors and risk of dementia among patients with type 2 diabetes and comorbid mental disorders: A population-based cohort study","volume":"50","author":"Hong","year":"2024","journal-title":"Diabetes Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-023-02063-6","article-title":"Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong","volume":"60","author":"Mui","year":"2023","journal-title":"Acta Diabetol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e079475","DOI":"10.1136\/bmj-2024-079475","article-title":"Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40\u201369 years with type 2 diabetes: population based cohort study","volume":"386","author":"Shin","year":"2024","journal-title":"BMJ"},{"key":"B21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2337\/dc22-1705","article-title":"Association of sodium-glucose cotransporter 2 inhibitors with time to dementia: A population-based cohort study","volume":"46","author":"Wu","year":"2023","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S164785","article-title":"12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus","volume":"10","author":"Perna","year":"2018","journal-title":"Clin Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"101131","DOI":"10.1016\/j.yfrne.2024.101131","article-title":"Sodium-glucose cotransporter-2 inhibitors and their potential role in dementia onset and cognitive function in patients with diabetes mellitus: a systematic review and meta-analysis","volume":"73","author":"Youn","year":"2024","journal-title":"Front Neuroendocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01538-1","article-title":"Risk of dementia in patients with diabetes using sodium-glucose transporter 2 inhibitors (SGLT2i): A systematic review, meta-analysis, and meta-regression","volume":"15","author":"Gunawan","year":"2024","journal-title":"Diabetes Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"101655","DOI":"10.1016\/j.diabet.2025.101655","article-title":"Comparative study of SGLT2 inhibitors and metformin: Evaluating first-line therapies for dementia prevention in type 2 diabetes","volume":"51","author":"Sun","year":"2025","journal-title":"Diabetes Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2019.00356","article-title":"Neuroprotective effects and treatment potential of incretin mimetics in a murine model of mild traumatic brain injury","volume":"7","author":"Bader","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.recesp.2021.06.016","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"74","author":"Page","year":"2021","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B29","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.00203","article-title":"Meta-analytic methodology for basic research: A practical guide","volume":"10","author":"Mikolajewicz","year":"2019","journal-title":"Front Physiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4097\/kja.25001","article-title":"Heterogeneity in meta-analyses: an unavoidable challenge worth exploring","volume":"78","author":"Choi","year":"2025","journal-title":"Korean J Anesthesiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1134025","article-title":"Oxidative stress: The nexus of obesity and cognitive dysfunction in diabetes","volume":"14","author":"Li","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.687157","article-title":"Insulin resistance exacerbates alzheimer disease via multiple mechanisms","volume":"15","author":"Wei","year":"2021","journal-title":"Front Neurosci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41392-023-01400-z","article-title":"Diabetic vascular diseases: molecular mechanisms and therapeutic strategies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.3390\/cells12151931","article-title":"Pericyte loss in diseases","volume":"12","author":"Li","year":"2023","journal-title":"Cells"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.18306","article-title":"Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies","volume":"71","author":"Tang","year":"2023","journal-title":"J Am Geriatr Soc"},{"key":"B37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/brainsci9030057","article-title":"Empagliflozin ameliorates type 2 diabetes-induced ultrastructural remodeling of the neurovascular unit and neuroglia in the female db\/db mouse","volume":"9","author":"Hayden","year":"2019","journal-title":"Brain Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13195-020-00607-4","article-title":"Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes","volume":"12","author":"Hierro-Bujalance","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s10735-024-10233-1","article-title":"SGLT2 inhibitor downregulated oxidative stress via activating AMPK pathway for cardiorenal (CR) protection in CR syndrome rodent fed with high protein diet","volume":"55","author":"Yang","year":"2024","journal-title":"J Mol Histol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"101061","DOI":"10.1016\/j.ajpc.2025.101061","article-title":"Sodium-glucose cotransporter 2 inhibitors and atherosclerosis","volume":"23","author":"Ceasovschih","year":"2025","journal-title":"Am J Prev Cardiol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1008922","article-title":"Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials","volume":"9","author":"Scisciola","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"123001","DOI":"10.1016\/j.lfs.2024.123001","article-title":"Repurposing antidiabetic drugs for Alzheimer's disease: A review of preclinical and clinical evidence and overcoming challenges","volume":"355","author":"Tran","year":"2024","journal-title":"Life Sci"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.3390\/biomedicines12122783","article-title":"The promising potency of sodium-glucose cotransporter 2 inhibitors in the prevention of and as treatment for cognitive impairment among type 2 diabetes patients","volume":"12","author":"Zhang","year":"2024","journal-title":"Biomedicines"},{"key":"B44","doi-asserted-by":"publisher","first-page":"108277","DOI":"10.1016\/j.pharmthera.2022.108277","article-title":"Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives","volume":"239","author":"Ferrari","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1361651","article-title":"Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer's disease: a narrative review","volume":"15","author":"Jiang","year":"2024","journal-title":"Front Pharmacol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2064","article-title":"Enhancement of impaired olfactory neural activation and cognitive capacity by liraglutide, but not dapagliflozin or acarbose, in patients with type 2 diabetes: a 16-week randomized parallel comparative study","volume":"45","author":"Cheng","year":"2022","journal-title":"Diabetes Care"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e020734","DOI":"10.1161\/JAHA.120.020734","article-title":"Activation of glucagon-like peptide-1 receptor ameliorates cognitive decline in type 2 diabetes mellitus through a metabolism-independent pathway","volume":"10","author":"Li","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-020-0535-5","article-title":"Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study","volume":"44","author":"Vadini","year":"2020","journal-title":"Int J Obes"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1177\/13872877251319054","article-title":"Effect of diabetes medications on the risk of developing dementia, mild cognitive impairment, or cognitive decline: A systematic review and meta-analysis","author":"Hui","year":"2025","journal-title":"J Alzheimers Dis"},{"key":"B50","doi-asserted-by":"publisher","first-page":"108276","DOI":"10.1016\/j.jstrokecerebrovasdis.2025.108276","article-title":"Comparative risk of dementia in diabetic stroke patients prescribed SGLT2 vs. DPP-4 inhibitors: A propensity-matched retrospective cohort study","volume":"34","author":"Chiang","year":"2025","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X22666240517094428","article-title":"Restoring brain pathways involved in diabetes-associated neurocognitive disorders: the potential of dipeptidyl peptidase 4 inhibitors as a therapeutic strategy","volume":"23","author":"Piatkowska-Chmiel","year":"2025","journal-title":"Curr Neuropharmacol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"112307","DOI":"10.1016\/j.exger.2023.112307","article-title":"Trelagliptin relieved cognitive impairment of diabetes mellitus rats: Involvement of PI3K\/Akt\/GSK-3\u03b2 and inflammation pathway","volume":"182","author":"Lei","year":"2023","journal-title":"Exp Gerontol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"117771","DOI":"10.1016\/j.biopha.2024.117771","article-title":"Positive impact of DPP-4 or SGLT2 inhibitors on mild cognitive impairment in type 2 diabetes patients on metformin therapy: A metabolomic mechanistic insight","volume":"182","author":"Osman","year":"2025","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B54","doi-asserted-by":"publisher","first-page":"123056","DOI":"10.1016\/j.lfs.2024.123056","article-title":"Nrf2 pathways in neuroprotection: Alleviating mitochondrial dysfunction and cognitive impairment in aging","volume":"357","author":"Bhat","year":"2024","journal-title":"Life Sci"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.944697","article-title":"Oxidative stress-mediated memory impairment during aging and its therapeutic intervention by natural bioactive compounds","volume":"14","author":"Singh","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001741","article-title":"Insulin sensitivity predicts cognitive decline in individuals with prediabetes","volume":"8","author":"Willmann","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.31662\/jmaj.2024-0083","article-title":"Harnessing the therapeutic potential of SGLT2 inhibitors in type 2 diabetes: challenges and opportunities","volume":"7","author":"Yabe","year":"2024","journal-title":"JMA J"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.62347\/MCEE4840","article-title":"Efficacy and safety of GLP-1 receptor agonists combined with SGLT-2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis","volume":"16","author":"Wu","year":"2024","journal-title":"Am J Transl Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2024.0317","article-title":"Benefit and safety of sodium-glucose co-transporter 2 inhibitors in older patients with type 2 diabetes mellitus","volume":"48","author":"Jeon","year":"2024","journal-title":"Diabetes Metab J"},{"key":"B60","doi-asserted-by":"publisher","first-page":"7213","DOI":"10.3390\/molecules26237213","article-title":"Neuroprotective effect of SGLT2 inhibitors","volume":"26","author":"Pawlos","year":"2021","journal-title":"Molecules"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.3390\/biomedicines12122797","article-title":"SGLT-2 inhibitors' and GLP-1 receptor agonists' Influence on neuronal and glial damage in experimental stroke","volume":"12","author":"Murasheva","year":"2024","journal-title":"Biomedicines"},{"key":"B62","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3390\/ijms26020542","article-title":"Associations between diabetes mellitus and neurodegenerative diseases","volume":"26","author":"Szablewski","year":"2025","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1695075\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:29:19Z","timestamp":1761715759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1695075\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":62,"alternative-id":["10.3389\/fendo.2025.1695075"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1695075","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"article-number":"1695075"}}